Valuation: Travere Therapeutics, Inc.

Capitalization 1.99B 1.9B 1.79B 1.58B 2.83B 173B 3.13B 21.32B 7.9B 72.23B 7.47B 7.32B 303B P/E ratio 2024 *
-6.2x
P/E ratio 2025 * -17.6x
Enterprise value 2.05B 1.95B 1.84B 1.63B 2.91B 178B 3.23B 21.95B 8.13B 74.38B 7.7B 7.54B 312B EV / Sales 2024 *
8.88x
EV / Sales 2025 * 5.53x
Free-Float
98.88%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart

Last Transcript: Travere Therapeutics, Inc.

1 day-3.41%
1 week+5.33%
Current month+11.97%
1 month+34.21%
3 months+24.04%
6 months+168.58%
Current year+31.52%
More quotes
1 week
20.28
Extreme 20.2846
25.29
1 month
18.04
Extreme 18.04
25.29
Current year
16.80
Extreme 16.8
25.29
1 year
5.12
Extreme 5.12
25.29
3 years
5.12
Extreme 5.12
30.35
5 years
5.12
Extreme 5.12
33.09
10 years
5.12
Extreme 5.12
37.04
More quotes
Director TitleAgeSince
Chief Executive Officer 52 2019-01-03
Director of Finance/CFO 41 2022-08-30
Chief Tech/Sci/R&D Officer 50 2022-01-03
Manager TitleAgeSince
Chairman 74 2016-05-17
Chairman 58 2015-06-07
Director/Board Member 58 2015-03-30
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi.($)
-3.41%+5.33%+177.70%-18.15% 1.99B
-0.77%-2.20%+9.84%+98.50% 118B
-0.10%-5.13%-28.93%+8.03% 72.09B
-2.13%-3.83%+68.23%+140.90% 38.79B
-2.40%+1.89%+31.02%-22.46% 28.73B
+2.38%+3.29%+58.26%+12.45% 24.63B
+4.61%+2.25%+11.97%-30.27% 23.61B
-2.06%+6.27%+380.22%+952.71% 15.76B
+0.81%-0.80%+189.03%+244.83% 14.19B
+0.94%+8.59%-19.89%-31.61% 13.46B
Average -0.21%+1.49%+87.74%+135.49% 35.11B
Weighted average by Cap. -0.28%-1.12%+37.28%+98.62%
See all sector performances

Financials

2024 *2025 *
Net sales 231M 220M 208M 183M 327M 20.02B 363M 2.47B 915M 8.37B 866M 849M 35.15B 362M 344M 325M 287M 513M 31.34B 569M 3.87B 1.43B 13.11B 1.36B 1.33B 55.02B
Net income -291M -277M -261M -231M -412M -25.21B -458M -3.11B -1.15B -10.54B -1.09B -1.07B -44.26B -117M -111M -105M -92.65M -166M -10.12B -184M -1.25B -463M -4.23B -438M -429M -17.77B
Net Debt 59.43M 56.58M 53.36M 47.13M 84.21M 5.15B 93.44M 635M 235M 2.15B 223M 218M 9.04B 7.1M 6.76M 6.38M 5.63M 10.06M 615M 11.16M 75.91M 28.12M 257M 26.62M 26.08M 1.08B
More financial data * Estimated data
Logo Travere Therapeutics, Inc.
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. It is also engaged in the identification of potential small molecule therapeutics for Alagille syndrome (ALGS).
Employees
380
More about the company
Date Price Change Volume
25-02-14 22.91 $ -3.41% 1,467,097
25-02-13 23.72 $ +2.24% 1,884,279
25-02-12 23.20 $ -2.32% 2,787,440
25-02-11 23.75 $ +12.56% 6,409,820
25-02-10 21.10 $ -2.99% 1,796,272

Delayed Quote Nasdaq, February 14, 2025 at 04:00 pm EST

More quotes
Trading Rating
Investor Rating
ESG MSCI
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
22.91USD
Average target price
32.27USD
Spread / Average Target
+40.84%
Consensus

Quarterly revenue - Rate of surprise